Long-term insulin glargine therapy in type 2 diabetes mellitus: a focus on cardiovascular outcomes
Vascular Health and Risk Management, 2015 Joshua J Joseph, Thomas W Donner Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA Abstract: Cardiovascular disease is the leading cause of mortality in type 2 ...
Joseph JJ, Donner TW
doaj
Journal of Diabetes Research, 2018 To achieve good metabolic control in diabetes and maintain it in the long term, a combination of changes in lifestyle and pharmacological treatment is necessary.
Hernando Vargas-Uricoechea
doaj +1 more source
Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. [PDF]
, 2000 L Heinemann +5 more
openalex +1 more source
United States experience of insulin Degludec alone or in combination for type 1 and type 2 diabetes
Drug Design, Development and Therapy, 2017 Marc Rendell1,2 1The Rose Salter Medical Research Foundation, 2The Association of Diabetes Investigators, Newport Coast, CA, USA Abstract: Insulin degludec has been the product of a sophisticated and systematic biochemical engineering program which ...
Rendell M
doaj
Increased hepatic PDGF-AA signaling mediates liver insulin resistance in obesity associated type 2 diabetes [PDF]
arXiv, 2017 Type 2 diabetes (T2D) is closely linked with non-alcoholic fatty liver disease (NAFLD) and hepatic insulin resistance, but the involved mechanisms are still elusive. Using DNA methylome and transcriptome analyses of livers from obese individuals, we found that both hypomethylation at a CpG site in PDGFA (encoding platelet derived growth factor alpha ...
arxiv
Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study Group of Insulin Glargine in Type 1 Diabetes. [PDF]
, 2000 Robert E. Ratner +5 more
openalex +1 more source
Качественная клиническая практика, 2019 Fixed antidiabetic drugs’ combinations have aim to improve of Diabetes Mellitus type 2 (DMT2) control as well as a safety treatment increasing. Soliqua SoloStar® is a new registered drug for control of fasting and prandial glucose levels, contained ...
S. К. Zyryanov, I. N. Dyakov
doaj +1 more source
The insulin-RB synapse in health and disease: cellular rocket science [PDF]
arXiv, 2007 Time has come for a survey of our knowledge on the physical interaction between the growth-promoting insulin molecule and retinoblastoma tumor suppressor protein (RB). Theoretical and experimental observations over the past 15 years reviewed here indicate that the insulin-RB dimer may represent an essential molecular crossroads involved in major ...
arxiv
A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes. [PDF]
, 2000 P. Raskin +5 more
openalex +1 more source
Cost Effectiveness and Resource AllocationBackground Type 1 Diabetes Mellitus (T1DM) is a life-threatening condition that is managed with administered insulin. Intermediate- to long-acting insulin represents the basal insulin constituent of the total insulin used in treating T1DM.
Mark T. Verryn, Susan Cleary
doaj +1 more source